Case number 1:22-cv-00513
Otsuka Pharmaceutical Co., Ltd. v. Teva Pharmaceuticals, Inc. et al > Documents
| Date Field | Doc. No. | Description (Pages) |
|---|---|---|
| Jun 27, 2024 | 140 | MOTION for Pro Hac Vice Appearance of Attorney Gabriel B. Ferrante - filed by Teva Pharmaceuticals USA, Inc., Teva Pharmaceuticals, Inc.. (DiBenedetto, Emily) (Entered: 06/27/2024) (4) |
| Jun 27, 2024 | 141 | Pro Hac Vice Fee - Credit Card Payment received for Gabriel B. Ferrante. ( re 140 MOTION for Pro Hac Vice Appearance of Attorney Gabriel B. Ferrante )( Payment of $ 50, receipt number ADEDC-4439542).(DiBenedetto, Emily) (Entered: 06/27/2024) (0) |
| Jun 25, 2024 | 139 | NOTICE OF SERVICE of Reply Expert Report of William R. Roush, Ph.D. Regarding Infringement of U.S. Patent Nos. 8,273,735 and 8,501,730 filed by Otsuka Pharmaceutical Co., Ltd..(Tigan, Jeremy) (Entered: 06/25/2024) (3) |
| Jun 24, 2024 | 138 | NOTICE OF SERVICE of 1) Reply Expert Report of Karl A. Scheidt, Ph.D. 2) Rebuttal Expert Report of David Blackburn, Ph.D. filed by Teva Pharmaceuticals USA, Inc., Teva Pharmaceuticals, Inc..(DiBenedetto, Emily) (Entered: 06/24/2024) (2) |
| Jun 21, 2024 | 137 | STIPULATION to Extend Time to regarding expert discovery - filed by Teva Pharmaceuticals USA, Inc., Teva Pharmaceuticals, Inc.. (Hoeschen, Nathan) Modified on 6/21/2024 (nms). (Entered: 06/21/2024) (2) |
| Jun 14, 2024 | 136 | REDACTED VERSION of 134 Reply Brief by Teva Pharmaceuticals USA, Inc., Teva Pharmaceuticals, Inc.. (Keller, Karen) (Entered: 06/14/2024) (16) |
| Jun 13, 2024 | 135 | REQUEST for Oral Argument by Otsuka Pharmaceutical Co., Ltd. re 117 MOTION for Summary Judgment of Non-Infringement. (Tigan, Jeremy) (Entered: 06/13/2024) (2) |
| Jun 7, 2024 | 131 | REDACTED VERSION of 126 Answering Brief in Opposition by Otsuka Pharmaceutical Co., Ltd.. (Tigan, Jeremy) (Entered: 06/07/2024) (27) |
| Jun 7, 2024 | 132 | REDACTED VERSION of 127 Appendix by Otsuka Pharmaceutical Co., Ltd.. (Attachments: # 1 Exhibits A-O)(Tigan, Jeremy) (Entered: 06/07/2024) (0) |
| Jun 7, 2024 | 133 | REDACTED VERSION of 128 Declaration by Otsuka Pharmaceutical Co., Ltd.. (Tigan, Jeremy) (Entered: 06/07/2024) (13) |
| Jun 7, 2024 | 134 | [SEALED] REPLY BRIEF re 117 MOTION for Summary Judgment of Non-Infringement filed by Teva Pharmaceuticals USA, Inc., Teva Pharmaceuticals, Inc.. (Hoeschen, Nathan) (Entered: 06/07/2024) (0) |
| Jun 6, 2024 | 129 | MOTION for Pro Hac Vice Appearance of Attorney Taskeen Aman - filed by Otsuka Pharmaceutical Co., Ltd.. (Tigan, Jeremy) (Entered: 06/06/2024) (3) |
| Jun 6, 2024 | 130 | Pro Hac Vice Fee - Credit Card Payment received for Taskeen Aman. ( re 129 MOTION for Pro Hac Vice Appearance of Attorney Taskeen Aman )( Payment of $ 50, receipt number ADEDC-4424064).(Tigan, Jeremy) (Entered: 06/06/2024) (0) |
| May 31, 2024 | 126 | [SEALED] ANSWERING BRIEF in Opposition re 117 MOTION for Summary Judgment of Non-Infringement filed by Otsuka Pharmaceutical Co., Ltd..Reply Brief due date per Local Rules is 6/7/2024. (Tigan, Jeremy) (Entered: 05/31/2024) (0) |
| May 31, 2024 | 127 | [SEALED] APPENDIX re 126 Answering Brief in Opposition by Otsuka Pharmaceutical Co., Ltd.. (Attachments: # 1 Exhibits A-O)(Tigan, Jeremy) (Entered: 05/31/2024) (0) |
| May 31, 2024 | 128 | [SEALED] DECLARATION re 126 Answering Brief in Opposition by Otsuka Pharmaceutical Co., Ltd.. (Tigan, Jeremy) (Entered: 05/31/2024) (0) |
| May 24, 2024 | 124 | NOTICE OF SERVICE of Rebuttal Expert Report of Karl A. Scheidt, Ph.D. filed by Teva Pharmaceuticals USA, Inc., Teva Pharmaceuticals, Inc..(DiBenedetto, Emily) (Entered: 05/24/2024) (2) |
| May 24, 2024 | 125 | NOTICE OF SERVICE of (1) Expert Report of Ron T. Gansevoort, M.D., Ph.D.; (2) Expert Report of John C. Jarosz; and (3) Responsive Expert Report of William R. Roush, Ph.D. Regarding Validity of U.S. Patent Nos. 8,273,735 and 8,501,730 filed by Otsuka Pharmaceutical Co., Ltd..(Tigan, Jeremy) (Entered: 05/24/2024) (3) |
| May 17, 2024 | 122 | REDACTED VERSION of 118 Opening Brief in Support, by Teva Pharmaceuticals USA, Inc., Teva Pharmaceuticals, Inc.. (DiBenedetto, Emily) (Entered: 05/17/2024) (22) |
| May 17, 2024 | 123 | REDACTED VERSION of 119 Appendix by Teva Pharmaceuticals USA, Inc., Teva Pharmaceuticals, Inc.. (DiBenedetto, Emily) (Entered: 05/17/2024) (30) |
| May 15, 2024 | 120 | Unopposed Motion to Extend Time to File Answering Brief in Opposition to Motion for Summary Judgment - filed by Otsuka Pharmaceutical Co., Ltd.. (Tigan, Jeremy) Modified on 5/15/2024 (nms). (Entered: 05/15/2024) (3) |
| May 15, 2024 | 121 | SO ORDERED, re 120 Unopposed Motion to Extend Time to File Answering Brief in Opposition to Motion for Summary Judgment (*Reset Briefing Schedule: re 117 MOTION for Summary Judgment of Non-Infringement. Answering Brief due 5/31/2024). Signed by Judge Richard G. Andrews on 5/15/2024. (nms) (Entered: 05/15/2024) (0) |
| May 10, 2024 | 117 | MOTION for Summary Judgment of Non-Infringement - filed by Teva Pharmaceuticals USA, Inc., Teva Pharmaceuticals, Inc.. (Attachments: # 1 Proposed Order)(Hoeschen, Nathan) Modified on 5/10/2024 (nms). (Entered: 05/10/2024) (0) |
| May 10, 2024 | 118 | [SEALED] OPENING BRIEF in Support re 117 MOTION for Summary Judgment of Non-Infringement, filed by Teva Pharmaceuticals USA, Inc., Teva Pharmaceuticals, Inc..Answering Brief/Response due date per Local Rules is 5/24/2024. (Hoeschen, Nathan) Modified on 5/10/2024 (nms). (Entered: 05/10/2024) (0) |
| May 10, 2024 | 119 | [SEALED] APPENDIX re 118 Opening Brief in Support, by Teva Pharmaceuticals USA, Inc., Teva Pharmaceuticals, Inc.. (Attachments: # 1 Exhibits A-I)(Hoeschen, Nathan) Modified on 5/10/2024 (nms). (Entered: 05/10/2024) (0) |
| May 3, 2024 | 116 | NOTICE requesting Clerk to remove Camille H. Mangiaratti as co-counsel. Reason for request: no longer with firm. (Tigan, Jeremy) (Entered: 05/03/2024) (2) |
| Apr 30, 2024 | 115 | ORAL ORDER: The Court read the letters. (D.I. 105 , 110 , 111 ). The request for leave to file a summary judgment motion is GRANTED. Defendants shall file the motion and their opening brief no later than May 14, 2024. Ordered by Judge Richard G. Andrews on 4/30/2024. (nms) (Entered: 04/30/2024) (0) |
| Apr 26, 2024 | 114 | REDACTED VERSION of 111 Letter by Teva Pharmaceuticals USA, Inc., Teva Pharmaceuticals, Inc.. (DiBenedetto, Emily) (Entered: 04/26/2024) (5) |
| Apr 23, 2024 | 112 | REDACTED VERSION of 105 Letter, by Teva Pharmaceuticals USA, Inc., Teva Pharmaceuticals, Inc.. (Hoeschen, Nathan) (Entered: 04/23/2024) (30) |
| Apr 23, 2024 | 113 | REDACTED VERSION of 110 Letter, by Otsuka Pharmaceutical Co., Ltd.. (Attachments: # 1 Exhibits A-F)(Tigan, Jeremy) Modified on 4/24/2024 (nms). (Entered: 04/23/2024) (0) |
| Apr 19, 2024 | 111 | [SEALED] Letter to The Honorable Richard G. Andrews, from Emily S. DiBenedetto, regarding request for leave to file Motion for Summary Judgment. (DiBenedetto, Emily) Modified on 4/22/2024 (nms). (Entered: 04/19/2024) (0) |
| Apr 16, 2024 | 109 | STIPULATION to Extend Time - filed by Teva Pharmaceuticals USA, Inc., Teva Pharmaceuticals, Inc.. (DiBenedetto, Emily) Modified on 4/16/2024 (nms). (Entered: 04/16/2024) (1) |
| Apr 16, 2024 | 110 | [SEALED] Letter to The Honorable Richard G. Andrews, from Jeremy A. Tigan, regarding opposition to request for leave to file motion for summary judgment. (Attachments: # 1 Exhibits A-F)(Tigan, Jeremy) Modified on 4/16/2024 (nms). (Entered: 04/16/2024) (0) |
| Apr 15, 2024 | 107 | Official Transcript of Discovery Dispute Hearing held on 4/4/24 before Judge Richard G. Andrews. Court Reporter Kimberly Bursner,Email: Kbursner@verizon.net. Transcript may be viewed at the court public terminal or order/purchased through the Court Reporter before the deadline for Release of Transcript Restriction. After that date, it may be obtained through PACER. Redaction Request due 5/6/2024. Redacted Transcript Deadline set for 5/16/2024. Release of Transcript Restriction set for 7/15/2024. (Triozzi, Heather) (Entered: 04/15/2024) (0) |
| Apr 15, 2024 | 108 | NOTICE OF SERVICE of Opening Expert Report of William R. Roush, Ph.D., Regarding Infringement of U.S. Patent Nos. 8,501,730 & 8,273,735 filed by Otsuka Pharmaceutical Co., Ltd..(Tigan, Jeremy) (Entered: 04/15/2024) (3) |
| Apr 12, 2024 | 106 | NOTICE OF SERVICE of Opening Expert Report of Karl A. Scheidt, Ph.D. filed by Teva Pharmaceuticals USA, Inc., Teva Pharmaceuticals, Inc..(Hoeschen, Nathan) (Entered: 04/12/2024) (2) |
| Apr 9, 2024 | 103 | REDACTED VERSION of 94 Letter, by Otsuka Pharmaceutical Co., Ltd.. (Attachments: # 1 Exhibits 1-13, # 2 Proposed Order)(Tigan, Jeremy) Modified on 4/10/2024 (nms). (Entered: 04/09/2024) (0) |
| Apr 9, 2024 | 104 | REDACTED VERSION of 95 Letter by Teva Pharmaceuticals USA, Inc., Teva Pharmaceuticals, Inc.. (DiBenedetto, Emily) (Entered: 04/09/2024) (25) |
| Apr 9, 2024 | 105 | [SEALED] Letter to The Honorable Richard G. Andrews from Karen E. Keller regarding Request for Leave to File Motion for Summary Judgment. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Exhibit E, # 6 Exhibit F, # 7 Exhibit G)(Keller, Karen) (Entered: 04/09/2024) (0) |
| Apr 3, 2024 | 101 | MOTION for Permission to Bring Electronic Devices into the J. Caleb Boggs Federal Building and United States Courthouse - filed by Teva Pharmaceuticals USA, Inc., Teva Pharmaceuticals, Inc.. (Attachments: # 1 Proposed Order)(DiBenedetto, Emily) Modified on 4/3/2024 (nms). (Entered: 04/03/2024) (0) |
| Apr 3, 2024 | 102 | ORDER Granting 101 MOTION for Permission to Bring Electronic Devices into the J. Caleb Boggs Federal Building and United States Courthouse. Signed by Judge Richard G. Andrews on 4/3/2024. (nms) (Entered: 04/03/2024) (1) |
| Apr 2, 2024 | 97 | STIPULATION to Extend Time to file redacted versions of DI 94 and DI 95 to April 9, 2024 - filed by Teva Pharmaceuticals USA, Inc., Teva Pharmaceuticals, Inc.. (DiBenedetto, Emily) Modified on 4/2/2024 (nms). (Entered: 04/02/2024) (2) |
| Apr 2, 2024 | 98 | SO ORDERED Granting [96 MOTION for Limited Exemption from the Standing Order Regarding Personal Electronic Devices. Signed by Judge Richard G. Andrews on 4/2/2024. (nms) (Entered: 04/02/2024) (2) |
| Apr 2, 2024 | 99 | MOTION for Pro Hac Vice Appearance of Attorney Anna Zhou - filed by Teva Pharmaceuticals USA, Inc., Teva Pharmaceuticals, Inc.. (DiBenedetto, Emily) (Entered: 04/02/2024) (3) |
| Apr 2, 2024 | 100 | Pro Hac Vice Fee - Credit Card Payment received for Anna Zhou. ( re 99 MOTION for Pro Hac Vice Appearance of Attorney Anna Zhou )( Payment of $ 50, receipt number ADEDC-4375345).(DiBenedetto, Emily) (Entered: 04/02/2024) (0) |
| Apr 1, 2024 | 96 | MOTION for Limited Exemption of Persons from the District of Delaware's May 15, 2023 Standing Order on Personal Devices - filed by Otsuka Pharmaceutical Co., Ltd.. (Tigan, Jeremy) (Entered: 04/01/2024) (3) |
| Mar 28, 2024 | 95 | [SEALED] Letter to The Honorable Richard G. Andrews, from Emily S. DiBenedetto, regarding opposition to motion to compel (D.I. 94 ). (Attachments: # 1 Exhibit 1, # 2 Exhibit 2)(DiBenedetto, Emily) Modified on 3/28/2024 (nms). (Entered: 03/28/2024) (0) |
| Mar 26, 2024 | 94 | [SEALED] Letter to The Honorable Richard G. Andrews, from Jeremy A. Tigan, regarding Otsuka's discovery dispute. (Attachments: # 1 Exhibits 1-13)(Tigan, Jeremy) (Additional attachment(s) added on 3/26/2024: # 2 Proposed Order) (nms). Modified on 3/26/2024 (nms). (Entered: 03/26/2024) (0) |
| Mar 25, 2024 | 93 | NOTICE to Take Deposition of ShigeKazu Fuijita on March 28, 2024, at 9:00 AM EST. filed by Teva Pharmaceuticals USA, Inc., Teva Pharmaceuticals, Inc..(DiBenedetto, Emily) (Entered: 03/25/2024) (2) |
| Mar 22, 2024 | 92 | ORAL ORDER: The parties have advised that a dispute has arisen requiring attention. The Court will hold a discovery conference on 4/4/2024, at 3:00 PM in Courtroom 6A. In preparation for this conference the parties shall follow the Discovery Matters and Disputes procedure as set forth in the Court's form Scheduling Order. Ordered by Judge Richard G. Andrews on 3/22/2024. (nms) (Entered: 03/22/2024) (0) |
| Mar 18, 2024 | 91 | NOTICE of Name Change of Counsel - Madeline R. DiLascia has changed her name to Madeline R. Bordynoski by Teva Pharmaceuticals USA, Inc., Teva Pharmaceuticals, Inc. (DiBenedetto, Emily) (Entered: 03/18/2024) (1) |
| Mar 15, 2024 | 90 | NOTICE OF SERVICE of 1. Teva's Second Supplemental Objections and Responses to Plaintiff's First Set of Interrogatories (Nos. 1 - 2) 2. Defendants' First Amended Invalidity Contentions filed by Teva Pharmaceuticals USA, Inc., Teva Pharmaceuticals, Inc..(DiBenedetto, Emily) (Entered: 03/15/2024) (2) |
| Feb 28, 2024 | 89 | STIPULATION and Proposed Order to Amend Discovery Deadlines - filed by Otsuka Pharmaceutical Co., Ltd.. (Tigan, Jeremy) Modified on 2/29/2024 (nms). (Entered: 02/28/2024) (2) |
| Feb 26, 2024 | 87 | MOTION for Pro Hac Vice Appearance of Attorney Stephen J. Krachie, Becky E. Steephenson, and Camille H. Mangiaratti - filed by Otsuka Pharmaceutical Co., Ltd.. (Tigan, Jeremy) (Entered: 02/26/2024) (6) |
| Feb 26, 2024 | 88 | Pro Hac Vice Fee - Credit Card Payment received for Stephen J. Krachie, Becky E. Steephenson, and Camille H. Mangiaratti. ( re 87 MOTION for Pro Hac Vice Appearance of Attorney Stephen J. Krachie, Becky E. Steephenson, and Camille H. Mangiaratti )( Payment of $ 150, receipt number ADEDC-4347355).(Tigan, Jeremy) (Entered: 02/26/2024) (0) |
| Feb 22, 2024 | 86 | NOTICE OF SERVICE of Otsuka Pharmaceutical Co., Ltd.'s Objections and Responses to Defendants' First Notice of Deposition Under Fed. R. Civ. P. 30(b)(6) filed by Otsuka Pharmaceutical Co., Ltd..(Tigan, Jeremy) (Entered: 02/22/2024) (3) |
| Feb 21, 2024 | 84 | MOTION for Pro Hac Vice Appearance of Attorney Eric T. Romeo and Madeline R. DiLascia - filed by Teva Pharmaceuticals USA, Inc., Teva Pharmaceuticals, Inc.. (Hoeschen, Nathan) (Entered: 02/21/2024) (5) |
| Feb 21, 2024 | 85 | Pro Hac Vice Fee - Credit Card Payment received for Eric T. Romeo and Madeline R. DiLascia. ( re 84 MOTION for Pro Hac Vice Appearance of Attorney Eric T. Romeo and Madeline R. DiLascia )( Payment of $ 100, receipt number ADEDC-4343251).(Hoeschen, Nathan) (Entered: 02/21/2024) (0) |
| Feb 20, 2024 | 83 | NOTICE OF SERVICE of 1) Defendants Teva Pharmaceuticals Inc. and Teva Pharmaceuticals USA, Inc.'s Objections and Responses to Plaintiff's Notice of Fed. R. Civ. P. 30(B)(6) Deposition; and 2) Defendants Teva Pharmaceuticals Inc. and Teva Pharmaceuticals USA, Inc.'s Objections and Responses to Plaintiff's Second Notice of Fed. R. Civ. P. 30(B)(6) Deposition filed by Teva Pharmaceuticals USA, Inc., Teva Pharmaceuticals, Inc..(DiBenedetto, Emily) (Entered: 02/20/2024) (2) |
| Feb 6, 2024 | 82 | NOTICE OF SERVICE of Otsuka Pharmaceutical Co., Ltd.'s Second Notice of Deposition Under Fed. R. Civ. P. 30(b)(6) to Defendants Teva Pharmaceuticals Inc. and Teva Pharmaceuticals USA, Inc. filed by Otsuka Pharmaceutical Co., Ltd..(Tigan, Jeremy) (Entered: 02/06/2024) (3) |
| Jan 11, 2024 | 81 | NOTICE requesting Clerk to remove Keith A. Zullow as co-counsel.. (DiBenedetto, Emily) (Entered: 01/11/2024) (1) |
| Dec 5, 2023 | 80 | NOTICE OF SERVICE of Teva's First Supplemental Objections and Responses to Plaintiff's First Set of Interrogatories (Nos. 1 - 2) filed by Teva Pharmaceuticals USA, Inc., Teva Pharmaceuticals, Inc..(DiBenedetto, Emily) (Entered: 12/05/2023) (2) |
| Dec 4, 2023 | 78 | NOTICE OF SERVICE of Tevas Objections and Responses to Plaintiffs Third Set of Interrogatories (Nos. 15-19) filed by Teva Pharmaceuticals USA, Inc., Teva Pharmaceuticals, Inc..(DiBenedetto, Emily) (Entered: 12/04/2023) (2) |
| Dec 4, 2023 | 79 | STIPULATION and [Proposed] Order to Amend Discovery Deadlines, by Otsuka Pharmaceutical Co., Ltd.. (Tigan, Jeremy) Modified on 12/4/2023 (nms). (Entered: 12/04/2023) (2) |
| Nov 3, 2023 | 77 | NOTICE OF SERVICE of Plaintiff's Third Set of Interrogatories to Defendants Teva Pharmaceuticals Inc. and Teva Pharmaceuticals USA, Inc. (Nos. 15-19) filed by Otsuka Pharmaceutical Co., Ltd..(Tigan, Jeremy) (Entered: 11/03/2023) (4) |
| Nov 2, 2023 | 76 | NOTICE OF SERVICE of Otsuka Pharmaceutical Co., Ltd.'s Notice of Deposition Under Fed. R. Civ. P. 30(b)(6) to Defendants Teva Pharmaceuticals Inc. and Teva Pharmaceuticals USA, Inc. filed by Otsuka Pharmaceutical Co., Ltd..(Tigan, Jeremy) (Entered: 11/02/2023) (4) |
| Oct 24, 2023 | 75 | NOTICE OF SERVICE of Defendants Teva Pharmaceuticals Inc. and Teva Pharmaceuticals USA, Inc.'s First Notice of Deposition Under Fed. R. Civ. P. 30(b)(6) to Plaintiff filed by Teva Pharmaceuticals USA, Inc., Teva Pharmaceuticals, Inc..(Keller, Karen) (Entered: 10/24/2023) (2) |
| Oct 20, 2023 | 74 | MEMORANDUM ORDER: Plaintiff's Motion for Leave to File First Amended Complaint (D.I. 53 ) is DENIED. As I find it unnecessary to consider further briefing on Plaintiffs motion, Defendants' Motion for Leave to File Sur-Reply Brief (D.I. 64 ) is DISMISSED as moot. Signed by Judge Richard G. Andrews on 10/20/2023. (nms) (Entered: 10/20/2023) (4) |
| Aug 25, 2023 | 73 | NOTICE OF SERVICE of Plaintiff Otsuka Pharmaceutical Co., Ltd.'s First Supplemental Responses and Objections to Defendants' Interrogatory No. 2 filed by Otsuka Pharmaceutical Co., Ltd..(Tigan, Jeremy) (Entered: 08/25/2023) (4) |
| Aug 1, 2023 | 71 | ORDER Granting Unopposed Motion to Redact Exhibits H, I and L (D.I. 69 ). Signed by Judge Richard G. Andrews on 8/1/2023. (nms) (Entered: 08/01/2023) (1) |
| Aug 1, 2023 | 72 | REDACTED VERSION of 68 Answering Brief in Opposition by Otsuka Pharmaceutical Co., Ltd.. (Tigan, Jeremy) (Entered: 08/01/2023) (11) |
| Jul 27, 2023 | 69 | Unopposed Motion to Redact Exhibits H, I and L - filed by Teva Pharmaceuticals USA, Inc., Teva Pharmaceuticals, Inc.. (Attachments: # 1 Proposed Order, # 2 Exhibit A, # 3 Exhibit H, # 4 Exhibit I, # 5 Exhibit L)(Hoeschen, Nathan) Modified on 7/27/2023 (nms). (Entered: 07/27/2023) (0) |
| Jul 27, 2023 | 70 | DECLARATION of Daniel Forchheimer re 69 Unopposed Motion to Redact Exhibits H, I and L, by Teva Pharmaceuticals USA, Inc., Teva Pharmaceuticals, Inc.. (Hoeschen, Nathan) Modified on 7/27/2023 (nms). (Entered: 07/27/2023) (3) |
| Jul 25, 2023 | 68 | [SEALED] ANSWERING BRIEF in Opposition re 64 MOTION for Leave to File to File Sur-Reply Brief filed by Otsuka Pharmaceutical Co., Ltd..Reply Brief due date per Local Rules is 8/1/2023. (Tigan, Jeremy) (Entered: 07/25/2023) (0) |
| Jul 20, 2023 | 67 | ORAL ORDER: The redacted filing (D.I. 66 ) is REJECTED because parts of it are redacted in its entirety. Absent a compelling reason, supported by a statement under oath by a party, redactions in their entirety are impermissible; redactions must be done so as to redact the least possible amount of the materials submitted. Failure to make a good faith attempt at such redactions may result in sanctions, the most common of which would be simply unsealing the entire filing. Redacting in its entirety a document, or parts of it, that contains publicly available materials is prima facie evidence of bad faith. A revised redacted filings is DUE within five business days. Ordered by Judge Richard G. Andrews on 7/20/2023. (nms) (Entered: 07/20/2023) (0) |
| Jul 19, 2023 | 66 | REDACTED VERSION of 59 Reply Brief, by Otsuka Pharmaceutical Co., Ltd.. (Attachments: # 1 Exhibits G-L)(Tigan, Jeremy) Modified on 7/19/2023 (nms). (Additional attachment(s) added on 8/1/2023: # 2 Exhibit H, # 3 Exhibit I, # 4 Exhibit L) (nms). (Entered: 07/19/2023) (0) |
| Jul 11, 2023 | 64 | MOTION for Leave to File to File Sur-Reply Brief - filed by Teva Pharmaceuticals USA, Inc., Teva Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Proposed Order)(Keller, Karen) Modified on 7/11/2023 (nms). (Entered: 07/11/2023) (0) |
| Jul 11, 2023 | 65 | STIPULATION and Order to Extend Time to file a redacted version of its Reply Brief (D.I. 59 ) to July 19, 2023 - filed by Otsuka Pharmaceutical Co., Ltd.. (Tigan, Jeremy) Modified on 7/12/2023 (nms). (Entered: 07/11/2023) (1) |
| Jul 5, 2023 | 60 | REDACTED VERSION of 57 Answering Brief in Opposition, by Teva Pharmaceuticals USA, Inc., Teva Pharmaceuticals, Inc.. (Hoeschen, Nathan) (Entered: 07/05/2023) (22) |
| Jul 5, 2023 | 61 | STIPULATION and Order to Extend Time to file a redacted version of D.I.59 to July 12, 2023 - filed by Otsuka Pharmaceutical Co., Ltd.. (Tigan, Jeremy) Modified on 7/5/2023 (nms). (Entered: 07/05/2023) (1) |
| Jul 5, 2023 | 62 | REDACTED VERSION of 53 MOTION for Leave to File First Amended Complaint to Add Zhejiang Huahai Pharmaceutcial Co., Ltd. as Defendant by Otsuka Pharmaceutical Co., Ltd.. (Attachments: # 1 Exhibit A, # 2 Exhibits A-F, # 3 Exhibit B)(Tigan, Jeremy) (Entered: 07/05/2023) (0) |
| Jul 5, 2023 | 63 | REDACTED VERSION of 54 Opening Brief in Support, by Otsuka Pharmaceutical Co., Ltd.. (Attachments: # 1 Exhibit C, # 2 Exhibit D, # 3 Exhibit E, # 4 Exhibit F)(Tigan, Jeremy) (Entered: 07/05/2023) (0) |
| Jun 28, 2023 | 58 | STIPULATION to Extend Time to file redacted versions of D.I. 53 and D.I. 54 to July 5, 2023 - filed by Teva Pharmaceuticals USA, Inc., Teva Pharmaceuticals, Inc.. (DiBenedetto, Emily) Modified on 6/28/2023 (nms). (Entered: 06/28/2023) (2) |
| Jun 28, 2023 | 59 | [SEALED] REPLY BRIEF re 53 MOTION for Leave to File First Amended Complaint to Add Zhejiang Huahai Pharmaceutcial Co., Ltd. as Defendant filed by Otsuka Pharmaceutical Co., Ltd.. (Attachments: # 1 Exhibits G-L)(Tigan, Jeremy) (Entered: 06/28/2023) (0) |
| Jun 21, 2023 | 56 | STIPULATION to Extend Time - filed by Teva Pharmaceuticals USA, Inc., Teva Pharmaceuticals, Inc.. (DiBenedetto, Emily) Modified on 6/21/2023 (nms). (Entered: 06/21/2023) (2) |
| Jun 21, 2023 | 57 | [SEALED] ANSWERING BRIEF in Opposition re 53 MOTION for Leave to File First Amended Complaint to Add Zhejiang Huahai Pharmaceutcial Co., Ltd. as Defendant filed by Teva Pharmaceuticals USA, Inc., Teva Pharmaceuticals, Inc..Reply Brief due date per Local Rules is 6/28/2023. (Hoeschen, Nathan) (Entered: 06/21/2023) (0) |
| Jun 14, 2023 | 55 | STIPULATION and Order to Extend Time to file redacted versions of Motion for Leave to File First Amended Complaint (D.I. 53) and Opening Brief (D.I. 54) to June 21, 2023 - filed by Otsuka Pharmaceutical Co., Ltd.. (Tigan, Jeremy) Modified on 6/15/2023 (nms). (Entered: 06/14/2023) (1) |
| Jun 7, 2023 | 53 | [SEALED] MOTION for Leave to File First Amended Complaint to Add Zhejiang Huahai Pharmaceutcial Co., Ltd. as Defendant - filed by Otsuka Pharmaceutical Co., Ltd.. (Attachments: # 1 Exhibit A, # 2 Exhibits A-F, # 3 Exhibit B)(Tigan, Jeremy) Modified on 6/7/2023 (nms). (Entered: 06/07/2023) (0) |
| Jun 7, 2023 | 54 | [SEALED] OPENING BRIEF in Support re 53 MOTION for Leave to File First Amended Complaint to Add Zhejiang Huahai Pharmaceutcial Co., Ltd. as Defendant, filed by Otsuka Pharmaceutical Co., Ltd..Answering Brief/Response due date per Local Rules is 6/21/2023. (Attachments: # 1 Exhibit C, # 2 Exhibit D, # 3 Exhibit E, # 4 Exhibit F)(Tigan, Jeremy) Modified on 6/7/2023 (nms). (Entered: 06/07/2023) (0) |
| May 24, 2023 | 52 | STIPULATION and [Proposed] Order to Amend the Deadline to Join Other Parties, and to Amend or Supplement the Pleadings to June 7, 2023 by Otsuka Pharmaceutical Co., Ltd.. (Tigan, Jeremy) (Entered: 05/24/2023) (2) |
| May 9, 2023 | 51 | STIPULATION and Proposed Order to Amend the Deadline to Join Other Parties, and to Amend or Supplement the Pleadings, by Otsuka Pharmaceutical Co., Ltd.. (Tigan, Jeremy) Modified on 5/10/2023 (nms). (Entered: 05/09/2023) (2) |
| Apr 24, 2023 | 50 | STIPULATION and [Proposed] Order to Amend the Deadline to Join Other Parties, and to Amend or Supplement the Pleadings, by Otsuka Pharmaceutical Co., Ltd.. (Tigan, Jeremy) Modified on 4/24/2023 (nms). (Entered: 04/24/2023) (2) |
| Apr 12, 2023 | 49 | STIPULATION and [Proposed] Order to Amend the Deadline to Join Other Parties, and to Amend or Supplement the Pleadings. by Otsuka Pharmaceutical Co., Ltd.. (Tigan, Jeremy) Modified on 4/12/2023 (nms). (Entered: 04/12/2023) (2) |
| Mar 27, 2023 | 48 | NOTICE OF SERVICE of (1) Plaintiff Otsuka Pharmaceutical Co., Ltd.'s Responses and Objections to Defendants' First Set of Requests for Admission (Nos. 1-3) and (2) Plaintiff Otsuka Pharmaceutical Co., Ltd.'s Responses and Objections to Defendants' Second Set of Interrogatories (Nos. 10-12) filed by Otsuka Pharmaceutical Co., Ltd..(Tigan, Jeremy) (Entered: 03/27/2023) (4) |
| Mar 24, 2023 | 47 | STIPULATION TO EXTEND TIME for deadline to join other parties, and to amend or supplement the pleadings to April 12, 2023 - filed by Otsuka Pharmaceutical Co., Ltd.. (Tigan, Jeremy) (Entered: 03/24/2023) (2) |
| Mar 7, 2023 | 46 | STIPULATION TO EXTEND TIME for deadline to join other parties, and to amend or supplement the pleadings to March 29, 2023 - filed by Otsuka Pharmaceutical Co., Ltd.. (Tigan, Jeremy) (Entered: 03/07/2023) (2) |
| Mar 1, 2023 | 45 | NOTICE OF SERVICE of Plaintiff Otsuka Pharmaceutical Co., Ltd.'s First Supplemental Responses and Objections to Defendants' First Set of Interrogatories (Nos. 1, 7) filed by Otsuka Pharmaceutical Co., Ltd..(Tigan, Jeremy) (Entered: 03/01/2023) (4) |
| Feb 27, 2023 | 44 | NOTICE OF SERVICE of 1. Defendants' Responses to Plaintiff's Second Set of Interrogatories (Nos. 3-14) 2. Defendants' Objections and Responses to Plaintiff's First Set of Requests for the Production of Documents and Things (Nos. 1-61) filed by Teva Pharmaceuticals USA, Inc., Teva Pharmaceuticals, Inc..(DiBenedetto, Emily) (Entered: 02/27/2023) (2) |
| Feb 23, 2023 | 43 | NOTICE OF SERVICE of 1. Defendants Teva Pharmaceuticals Inc. and Teva Pharmaceuticals USA, Inc.'s Second Set of Interrogatories to Plaintiff (Nos. 10 - 12) 2. Defendants Teva Pharmaceuticals Inc. and Teva Pharmaceuticals USA, Inc.'s First Set of Requests for Admission to Plaintiff (Nos. 1 - 3) filed by Teva Pharmaceuticals USA, Inc., Teva Pharmaceuticals, Inc..(Keller, Karen) (Entered: 02/23/2023) (2) |
| Jan 27, 2023 | 41 | Joint Letter to The Honorable Richard G. Andrews, from Jeremy A. Tigan, regarding the construction of claim terms in U.S. Patent Nos. 8,501,730 and 8,273,735. (Tigan, Jeremy) Modified on 1/27/2023 (nms). (Entered: 01/27/2023) (2) |
| Jan 27, 2023 | 42 | ORAL ORDER: The request to cancel the Markman hearing (D.I. 41 ) is GRANTED. Ordered by Judge Richard G. Andrews on 1/27/2023. (nms) (Entered: 01/27/2023) (0) |
| Jan 26, 2023 | 40 | NOTICE OF SERVICE of (1) Otsuka Pharmaceutical Co., Ltd.'s First Set of Requests to Defendants for the Production of Documents and Things (Nos. 1-61) and (2) Plaintiff's Second Set of Interrogatories to Defendants Teva Pharmaceuticals Inc. and Teva Pharmaceuticals USA, Inc. (Nos. 3-14) filed by Otsuka Pharmaceutical Co., Ltd..(Tigan, Jeremy) (Entered: 01/26/2023) (4) |
| Jan 17, 2023 | 39 | NOTICE OF SERVICE of Teva's Objections and Responses to Plaintiffs' First Set of Interrogatories (Nos. 1-2) filed by Teva Pharmaceuticals USA, Inc., Teva Pharmaceuticals, Inc..(DiBenedetto, Emily) (Entered: 01/17/2023) (2) |
| Jan 12, 2023 | 38 | STIPULATION TO EXTEND TIME for the parties to exchange a list of terms needing construction and proposed constructions to January 17, 2023 - filed by Teva Pharmaceuticals USA, Inc., Teva Pharmaceuticals, Inc.. (DiBenedetto, Emily) (Entered: 01/12/2023) (2) |
| Dec 19, 2022 | 36 | STIPULATION and [Proposed] Order Dismissing Otsuka's '694 Patent Claims Against Teva and Teva's Counterclaims on the '694 Patent by Otsuka Pharmaceutical Co., Ltd.. (Tigan, Jeremy) (Entered: 12/19/2022) (3) |
| Dec 19, 2022 | 37 | SO ORDERED Granting 36 Stipulation and Proposed Order Dismissing Otsuka's '694 Patent Claims Against Teva and Teva's Counterclaims on the '694 Patent. Signed by Judge Richard G. Andrews on 12/19/2022. (nms) (Entered: 12/19/2022) (3) |
| Dec 15, 2022 | 35 | NOTICE OF SERVICE of Plaintiff's First Set of Interrogatories to Defendants Teva Pharmaceuticals Inc. and Teva Pharmaceuticals USA, Inc. (Nos. 1-2) filed by Otsuka Pharmaceutical Co., Ltd..(Blumenfeld, Jack) (Entered: 12/15/2022) (4) |
| Dec 5, 2022 | 34 | NOTICE OF SERVICE of (1) Plaintiff Otsuka Pharmaceutical Co., Ltd.'s Responses and Objections to Defendants' First Set of Interrogatories (Nos. 1-9) and (2) Plaintiff Otsuka Pharmaceutical Co., Ltd.'s Responses and Objections to Defendants' First Set of Requests for the Production of Documents and Things (Nos. 1-45) filed by Otsuka Pharmaceutical Co., Ltd..(Tigan, Jeremy) (Entered: 12/05/2022) (4) |
| Dec 1, 2022 | 32 | STIPULATION and Order regarding claim construction deadlines - filed by Otsuka Pharmaceutical Co., Ltd.. (Tigan, Jeremy) Modified on 12/1/2022 (nms). (Entered: 12/01/2022) (2) |
| Dec 1, 2022 | 33 | SO ORDERED Granting 32 STIPULATION and Order (*Reset Deadlines/Hearings: Joint Claim Construction Brief due by 5/12/2023, Markman Hearing is now set for 6/20/2023, at 9:00 AM in Courtroom 6A). Signed by Judge Richard G. Andrews on 12/1/2022. (nms) (Entered: 12/01/2022) (2) |
| Nov 17, 2022 | 31 | NOTICE OF SERVICE of Defendants' Initial Invalidity Contentions filed by Teva Pharmaceuticals USA, Inc., Teva Pharmaceuticals, Inc..(Hoeschen, Nathan) (Entered: 11/17/2022) (2) |
| Nov 3, 2022 | 30 | NOTICE OF SERVICE of 1. Defendants Teva Pharmaceuticals Inc. and Teva Pharmaceuticals USA, Inc.'s First Set of Interrogatories to Plaintiff (Nos. 1-9) 2. Defendants Teva Pharmaceuticals Inc. and Teva Pharmaceuticals USA, Inc.'s First Set of Requests for the Production of Documents and Things to Plaintiff (Nos. 1-45) filed by Teva Pharmaceuticals USA, Inc., Teva Pharmaceuticals, Inc..(Hoeschen, Nathan) (Entered: 11/03/2022) (2) |
| Oct 18, 2022 | 29 | NOTICE OF SERVICE of Otsuka Pharmaceutical Co., Ltd.'s Initial Infringement Contentions filed by Otsuka Pharmaceutical Co., Ltd..(Tigan, Jeremy) (Entered: 10/18/2022) (4) |
| Sep 23, 2022 | 27 | NOTICE OF SERVICE of (1) Plaintiff's Initial Disclosure Statement Pursuant to Fed. R. Civ. P. 26(a)(1) and (2) Plaintiff's Initial Disclosures Pursuant to Paragraph 3 of the Delaware Default Standard for Discovery filed by Otsuka Pharmaceutical Co., Ltd..(Tigan, Jeremy) (Entered: 09/23/2022) (4) |
| Sep 23, 2022 | 28 | NOTICE OF SERVICE of Defendant Teva Pharmaceuticals Inc. and Teva Pharmaceuticals USA, Inc.'s Initial Disclosures Pursuant to Fed. R. Civ. P. 26(a) and the Delaware Default Standard for Discovery filed by Teva Pharmaceuticals USA, Inc., Teva Pharmaceuticals, Inc..(Hoeschen, Nathan) (Entered: 09/23/2022) (2) |
| Sep 6, 2022 | 25 | PROPOSED Stipulated Protective Order, by Otsuka Pharmaceutical Co., Ltd.. (Tigan, Jeremy) Modified on 9/6/2022 (nms). (Entered: 09/06/2022) (29) |
| Sep 6, 2022 | 26 | SO ORDERED Granting 25 Stipulated Protective Order. Signed by Judge Richard G. Andrews on 9/6/2022. (nms) (Entered: 09/06/2022) (29) |
| Sep 2, 2022 | 24 | NOTICE OF SERVICE of Plaintiff's Disclosures Pursuant to the District of Delaware Default Standard for Discovery Paragraph 4(a) filed by Otsuka Pharmaceutical Co., Ltd..(Tigan, Jeremy) (Entered: 09/02/2022) (4) |
| Sep 1, 2022 | 23 | Official Transcript of Teleconference held on 8/18/22 before Judge Richard G. Andrews. Court Reporter Heather M. Triozzi,Email: Heather_Triozzi@ded.uscourts.gov. Transcript may be viewed at the court public terminal or order/purchased through the Court Reporter before the deadline for Release of Transcript Restriction. After that date, it may be obtained through PACER. Redaction Request due 9/22/2022. Redacted Transcript Deadline set for 10/3/2022. Release of Transcript Restriction set for 11/30/2022. (Triozzi, Heather) (Entered: 09/01/2022) (18) |
| Aug 24, 2022 | 22 | SCHEDULING ORDER: Joinder of Parties due by 3/8/2023. Amended Pleadings due by 3/8/2023. Fact Discovery completed by 12/4/2023. Joint Claim Construction Brief due by 3/31/2023. A Markman Hearing is set for 5/3/2023, at 9:00 AM in Courtroom 6A. A Pretrial Conference is set for 10/4/2024, at 9:00 AM in Courtroom 6A. A 3 day Bench Trial is set to start 10/15/2024, at 8:30 AM in Courtroom 6A (see Order for further details). Signed by Judge Richard G. Andrews on 8/24/2022. (nms) (Entered: 08/24/2022) (10) |
| Aug 23, 2022 | 21 | PROPOSED Scheduling Order, by Otsuka Pharmaceutical Co., Ltd.. (Tigan, Jeremy) Modified on 8/23/2022 (nms). (Entered: 08/23/2022) (11) |
| Aug 17, 2022 | 18 | Letter to The Honorable Richard G. Andrews from Jeremy A. Tigan regarding dial-in number for August 18, 2022 Rule 16 conference. (Tigan, Jeremy) (Entered: 08/17/2022) (1) |
| Aug 17, 2022 | 19 | ORAL ORDER: The parties in No. 22-513 submitted a scheduling proposal (D.I. 17) wherein Defendant Teva requests the case be consolidated with the case against Lupin in No. 21-900. Tevas proposed schedule includes no Markman hearing (as the Markman hearing in Otsuka v. Lupin has already been held and resolved), and trial on the same date (Dec. 18, 2023) as the Otsuka v. Lupin trial. The Court would like to consolidate the two cases, but will not do so without first hearing from Lupin. The Court also notes that in both cases, launch appears to be prohibited until at the earliest April 2025 (No. 22-513, D.I. 17 at 11 n.4; No. 21-900, D.I. 16 at 10 n.3), meaning that there is flexibility in scheduling the trial. The Court requests that Teva submit a letter by COB today describing generally any conversations it has had with Lupin about consolidation. The Court requests that Lupin submit a letter by COB today setting forth its position on consolidation. (If Lupin needs more time to think about it, Lupin should say so.) Ordered by Judge Richard G. Andrews on 8/17/2022. Associated Cases: 1:22-cv-00513-RGA, 1:21-cv-00900-RGA(nms) (Entered: 08/17/2022) (0) |
| Aug 17, 2022 | 20 | Letter to The Honorable Richard G. Andrews, from Karen E. Keller, regarding Teva's discussions with Lupin regarding consolidation. (Keller, Karen) Modified on 8/17/2022 (nms). (Entered: 08/17/2022) (2) |
| Aug 16, 2022 | 17 | PROPOSED Scheduling Order, by Otsuka Pharmaceutical Co., Ltd.. (Tigan, Jeremy) Modified on 8/16/2022 (nms). (Entered: 08/16/2022) (13) |
| Aug 2, 2022 | 16 | Answer to Counterclaim (9) Docket Text: ANSWER to [12] Answer to Complaint, Counterclaim by Otsuka Pharmaceutical Co., Ltd..(Tigan, Jeremy) |
| Jul 29, 2022 | 15 | Order Setting Scheduling Conference (1) Docket Text: Order Setting Rule 16(b) Telephone Conference: A Scheduling Conference is set for 8/18/2022, at 9:00 AM before Judge Richard G. Andrews (see Order for further details). Signed by Judge Richard G. Andrews on 7/29/2022. (nms) |
| Jul 13, 2022 | N/A | SO ORDERED (0) Docket Text: SO ORDERED, re [14] MOTION for Pro Hac Vice Appearance of Attorney Keith A. Zullow, Jenny J. Zhang, Elaine H. Blais, and Harrison C. Gunn, filed by Teva Pharmaceuticals, Inc., Teva Pharmaceuticals USA, Inc.. Signed by Judge Richard G. Andrews on 7/13/2022. (nms) |
| Jul 13, 2022 | N/A | Add Attorneys Pro Hac Vice (0) Docket Text: Pro Hac Vice Attorney Elaine H. Blais, Harrison Gunn, Jenny J Zhang, and Keith A. Zullow for Teva Pharmaceuticals, Inc. added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. (mpb) |
| Jul 12, 2022 | 12 | Answer to Complaint (23) Docket Text: ANSWER to [1] Complaint, Affirmative Defenses, and COUNTERCLAIMS against Otsuka Pharmaceutical Co., Ltd., by Teva Pharmaceuticals, Inc., Teva Pharmaceuticals USA, Inc..(DiBenedetto, Emily) Modified on 7/13/2022 (nms). |
| Jul 12, 2022 | 13 | Disclosure Statement (2) Docket Text: Disclosure Statement pursuant to Rule 7.1: identifying Other Affiliate Teva Pharmaceutical Industries Ltd. for Teva Pharmaceuticals USA, Inc., Teva Pharmaceuticals, Inc. filed by Teva Pharmaceuticals USA, Inc., Teva Pharmaceuticals, Inc.. (DiBenedetto, Emily) |
| Jul 12, 2022 | 14 | Motion for Leave to Appear Pro Hac Vice (7) Docket Text: MOTION for Pro Hac Vice Appearance of Attorney Keith A. Zullow, Jenny J. Zhang, Elaine H. Blais, and Harrison C. Gunn - filed by Teva Pharmaceuticals USA, Inc., Teva Pharmaceuticals, Inc.. (DiBenedetto, Emily) |
| Jun 2, 2022 | 10 | Stipulation (4) Docket Text: STIPULATION and Proposed Order of Dismissal, by Teva Pharmaceuticals USA, Inc., Teva Pharmaceuticals, Inc.. (Keller, Karen) Modified on 6/2/2022 (nms). |
| Jun 2, 2022 | 11 | Order (4) Docket Text: SO ORDERED Granting [10] Stipulation and Proposed Order (*Party Teva Pharmaceutical Industries Ltd. terminated). Signed by Judge Richard G. Andrews on 6/2/2022. (nms) |
| May 17, 2022 | 9 | Waiver of Service Executed (1) Docket Text: WAIVER OF SERVICE returned executed by Teva Pharmaceuticals, Inc., Teva Pharmaceuticals USA, Inc.: For Teva Pharmaceuticals, Inc. waiver sent on 5/13/2022, answer due 7/12/2022; Teva Pharmaceuticals USA, Inc. waiver sent on 5/13/2022, answer due 7/12/2022. (Keller, Karen) |
| Apr 27, 2022 | N/A | Case Assigned/Reassigned (0) Docket Text: Case Assigned to Judge Richard G. Andrews. Please include the initials of the Judge (RGA) after the case number on all documents filed. (rjb) |
| Apr 22, 2022 | 1 | Main Document (13) Docket Text: COMPLAINT FOR PATENT INFRINGEMENT filed against Teva Pharmaceutical Industries Ltd., Teva Pharmaceuticals USA, Inc., Teva Pharmaceuticals, Inc. - Magistrate Consent Notice to Pltf. ( Filing fee $ 402, receipt number ADEDC-3857538.) - filed by Otsuka Pharmaceutical Co., Ltd.. (Attachments: # (1) Exhibit A-c , # (2) Civil Cover Sheet)(srs) |
| Apr 22, 2022 | 1 | Exhibit A-c (51) |
| Apr 22, 2022 | 1 | Civil Cover Sheet (2) |
| Apr 22, 2022 | 2 | Magistrate Consent Forms (3) Docket Text: Notice, Consent and Referral forms re: U.S. Magistrate Judge jurisdiction. (srs) |
| Apr 22, 2022 | 3 | ANDA Form (2) Docket Text: Supplemental information for patent cases involving an Abbreviated New Drug Application (ANDA) - Date Patentee(s) Received Notice: March 9, 2022. Date of Expiration of the 730 Patent: September 1, 2026. Date of Expiration of the 694 Patent: April 7, 2030. Date of Expiration of the 735 Patent: August 14, 2028.Thirty Month Stay Deadline: September 9, 2024. (srs) |
| Apr 22, 2022 | 4 | Patent/Trademark Report to Commissioner (1) Docket Text: Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 8,501,730 B2 ;10,905,694 B2 ;8,273,735 B2. (srs) |
| Apr 22, 2022 | 5 | Disclosure Statement (1) Docket Text: Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent Otsuka Holdings Co., Ltd. for Otsuka Pharmaceutical Co., Ltd. filed by Otsuka Pharmaceutical Co., Ltd. (srs) |
| Apr 22, 2022 | 6 | Summons Issued (2) Docket Text: Summons Issued as to Teva Pharmaceuticals, Inc. on 4/22/2022. (srs) |
| Apr 22, 2022 | 7 | Summons Issued (2) Docket Text: Summons Issued as to Teva Pharmaceutical Industries Ltd. on 4/22/2022. (srs) |
| Apr 22, 2022 | 8 | Summons Issued (2) Docket Text: Summons Issued as to Teva Pharmaceuticals USA, Inc. on 4/22/2022. (srs) |
| Apr 22, 2022 | 1 | Complaint* (1) |
